Movatterモバイル変換

[0]ホーム
URL:

ES2563677T3 - Composiciones de combinaciones de Neisseria - Google Patents

Composiciones de combinaciones de NeisseriaDownload PDF

Info

Publication number
ES2563677T3
ES2563677T3ES10179061.6TES10179061TES2563677T3ES 2563677 T3ES2563677 T3ES 2563677T3ES 10179061 TES10179061 TES 10179061TES 2563677 T3ES2563677 T3ES 2563677T3
Authority
ES
Spain
Prior art keywords
seq
sequence
amino acid
pairs
protein comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10179061.6T
Other languages
English (en)
Inventor
Marzia Monica Giuliani
Mariagrazia Pizza
Rino Rappuoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911692.3Aexternal-prioritypatent/GB9911692D0/en
Priority claimed from GBGB9919705.5Aexternal-prioritypatent/GB9919705D0/en
Priority claimed from GB0005730Aexternal-prioritypatent/GB0005730D0/en
Application filed by GlaxoSmithKline Biologicals SAfiledCriticalGlaxoSmithKline Biologicals SA
Application grantedgrantedCritical
Publication of ES2563677T3publicationCriticalpatent/ES2563677T3/es
Anticipated expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

Una composición que comprende dos o más proteínas de Neisseria diferentes, en la que las dos o más proteínas de Neisseria diferentes incluyen una primera proteína de una bacteria de Neisseria y una segunda proteína de una bacteria de Neisseria, y en la que (i) la primera proteína comprende una secuencia de aminoácidos seleccionada de (a) SEC ID Nº: 3898; y (b) una secuencia que tiene una identidad de secuencia mayor del 80 % con la SEC ID Nº: 3898; y la segunda proteína comprende una secuencia de aminoácidos seleccionada de (a) una de las SEC ID Nº pares seleccionadas de las SEC ID Nº: 2182 a 2186; y (b) una secuencia que tiene una identidad de secuencia mayor del 80 % con una de las SEC ID Nº: 2182 a 2186 pares; o (ii) la primera proteína comprende una secuencia de aminoácidos seleccionada de (a) SEC ID Nº: 3900; y (b) una secuencia que tiene una identidad de secuencia mayor del 80 % con la SEC ID Nº: 3900; y la segunda proteína comprende una secuencia de aminoácidos seleccionada de (a) una de las SEC ID Nº pares seleccionadas de las SEC ID Nº: 2182 a 2186; y (b) una secuencia que tiene una identidad de secuencia mayor del 80 % con una de las SEC ID Nº: 2182 a 2186 pares; o (iii) la primera proteína comprende una secuencia de aminoácidos seleccionada de (a) SEC ID Nº: 3902; y (b) una secuencia que tiene una identidad de secuencia mayor del 80 % con la SEC ID Nº: 3902; y la segunda proteína comprende una secuencia de aminoácidos seleccionada de (a) una de las SEC ID Nº pares seleccionadas de las SEC ID Nº: 2182 a 2186; y (b) una secuencia que tiene una identidad de secuencia mayor del 80 % con una de las SEC ID Nº: 2182 a 2186 pares.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

ES10179061.6T1999-05-192000-05-19Composiciones de combinaciones de NeisseriaExpired - LifetimeES2563677T3 (es)

Applications Claiming Priority (6)

Application NumberPriority DateFiling DateTitle
GB99116921999-05-19
GBGB9911692.3AGB9911692D0 (en)1999-05-191999-05-19Antigenic combinations
GBGB9919705.5AGB9919705D0 (en)1999-08-191999-08-19Antigenic combinations
GB99197051999-08-19
GB00057302000-03-09
GB0005730AGB0005730D0 (en)2000-03-092000-03-09Antigenic combinations

Publications (1)

Publication NumberPublication Date
ES2563677T3true ES2563677T3 (es)2016-03-15

Family

ID=27255587

Family Applications (2)

Application NumberTitlePriority DateFiling Date
ES10179061.6TExpired - LifetimeES2563677T3 (es)1999-05-192000-05-19Composiciones de combinaciones de Neisseria
ES10178238.1TExpired - LifetimeES2563650T3 (es)1999-05-192000-05-19Composiciones de combinaciones de Neisseria

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
ES10178238.1TExpired - LifetimeES2563650T3 (es)1999-05-192000-05-19Composiciones de combinaciones de Neisseria

Country Status (14)

CountryLink
US (9)US7862827B2 (es)
EP (6)EP2258851A1 (es)
JP (3)JP5622344B2 (es)
CN (2)CN100338218C (es)
AU (3)AU783894B2 (es)
BR (1)BR0010721A (es)
CA (3)CA2929348A1 (es)
CY (2)CY1117239T1 (es)
DK (2)DK2270173T3 (es)
ES (2)ES2563677T3 (es)
MX (1)MXPA01011867A (es)
NZ (4)NZ536676A (es)
PT (2)PT2270173E (es)
WO (1)WO2000071725A2 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP1860192A1 (en)1996-09-172007-11-28Novartis Vaccines and Diagnostics, Inc.Compositions and methods for treating intracellular diseases
BR9910089A (pt)*1998-05-012004-06-08Chiron CorpComposições e antìgenos de neisseria meningitidis
GB9823978D0 (en)*1998-11-021998-12-30Microbiological Res AuthorityMulticomponent meningococcal vaccine
US10967045B2 (en)*1998-11-022021-04-06Secretary of State for Health and Social CareMulticomponent meningococcal vaccine
ES2397918T3 (es)1999-04-302013-03-12Novartis Vaccines And Diagnostics S.R.L.Antígenos Neisseriales conservados
DK2270173T3 (en)1999-05-192016-03-07Glaxosmithkline Biolog SaNeisserial combination compositions
GB9916529D0 (en)*1999-07-141999-09-15Chiron SpaAntigenic peptides
CN1796404A (zh)*1999-10-292006-07-05启龙有限公司奈瑟球菌的抗原性肽
GB9928196D0 (en)*1999-11-292000-01-26Chiron SpaCombinations of B, C and other antigens
CN1201011C (zh)*2000-02-282005-05-11启龙股份公司奈瑟球菌蛋白质的异源表达
AU2004203417B2 (en)*2000-05-082008-02-14Microscience LimitedVirulence genes, proteins, and their use
GB0012079D0 (en)*2000-05-182000-07-12Microscience LtdVirulence gene and protein, and their use
GB0020952D0 (en)*2000-08-242000-10-11Microscience LtdGenes and proteins and their uses
EA006947B1 (ru)2001-01-232006-06-30Авентис ПастерПоливалентная менингококковая полисахаридно-белковая конъюгированная вакцина
US7261901B2 (en)2001-01-312007-08-28University Of Iowa Research FoundationVaccine and compositions for the prevention and treatment of neisserial infections
WO2002060936A2 (en)*2001-01-312002-08-08University Of Iowa Research FoundationVaccine and compositions for the prevention and treatment of neisserial infections
GB0108024D0 (en)2001-03-302001-05-23Chiron SpaBacterial toxins
GB0114940D0 (en)*2001-06-192001-08-08Chiron SpaGene expression during meningococcus adhesion
GB0115176D0 (en)2001-06-202001-08-15Chiron SpaCapular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en)2001-07-262001-09-19Chiron SpaHistidine vaccines
US20050232936A1 (en)2001-07-272005-10-20Chiron CorporationMeningococcus adhesins nada, app and orf 40
GB0121591D0 (en)2001-09-062001-10-24Chiron SpaHybrid and tandem expression of neisserial proteins
AU2012202488B2 (en)*2001-09-062014-01-16Glaxosmithkline Biologicals S.A.Hybrid and tandem expression of Neisserial proteins
MX339524B (es)2001-10-112016-05-30Wyeth CorpComposiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
BR0313100A (pt)*2002-08-022005-06-21Glaxosmithkline Biolog SaComposição imunogênica, composição imunogênica isolada, vacina, método de tratamento ou prevenção de doença bacteriana gram-negativa, uso da vacina, cepa bacteriana gram-negativa geneticamente manipulada, método para preparar a composição imunogênica, método para preparar a vacina, método de preparar uma imunoglobulina para uso na prevenção ou tratamento de infecção neisserial, preparação de imunoglobulina, preparação farmacêutica, e, uso da preparação farmacêutica
GB0220197D0 (en)*2002-08-302002-10-09Univ UtrechtRefolding method
SI1524993T1 (sl)2002-08-022013-07-31Glaxosmithkline Biologicals S.A.Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
GB0220194D0 (en)2002-08-302002-10-09Chiron SpaImproved vesicles
CN1809380B (zh)2002-10-112010-05-12启龙有限公司广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
US20070059329A1 (en)*2002-11-152007-03-15Nathalie NoraisUnexpected surface proteins in meningococcus
GB0227346D0 (en)2002-11-222002-12-31Chiron Spa741
GB0315021D0 (en)*2003-06-262003-07-30Chiron SrlImmunogenic gonococcal compositions
GB0408977D0 (en)2004-04-222004-05-26Chiron SrlImmunising against meningococcal serogroup Y using proteins
GB0419408D0 (en)*2004-09-012004-10-06Chiron Srl741 chimeric polypeptides
EP1856291A4 (en)*2005-03-042009-04-01Verenium Corp NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME
GB0524066D0 (en)2005-11-252006-01-04Chiron Srl741 ii
RU2008130395A (ru)*2005-12-232010-01-27Империал Инновейшенс Лимитед (Gb)Вакцины и их применение
CU23575A1 (es)*2006-03-312010-09-30Ct Ingenieria Genetica BiotechComposición farmacéutica que comprende la proteína nmb0606
CU23572A1 (es)*2006-03-312010-09-30Ct Ingenieria Genetica BiotechComposición farmacéutica que comprende la proteína nmb0938
BRPI0713904A2 (pt)*2006-06-292013-06-25Novartis AgpolipeptÍdeos a partir de neisseria meningitidis
AR064642A1 (es)2006-12-222009-04-15Wyeth CorpPolinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
ES2532946T3 (es)2008-02-212015-04-06Novartis AgPolipéptidos PUfH meningocócicos
GB0810742D0 (en)*2008-06-122008-07-16Univ NottinghamEnzyme
WO2010028246A2 (en)*2008-09-052010-03-11Id Biomedical Corporation Of QuebecNovel compositions and adjuvants
GB0816447D0 (en)*2008-09-082008-10-15Glaxosmithkline Biolog SaVaccine
IT1394288B1 (it)*2008-09-122012-06-06Novartis Vaccines & DiagnosticImmunogeni di proteine che legano il fattore h.
AU2010227219B2 (en)2009-03-242014-02-27Glaxosmithkline Biologicals S.A.Adjuvanting meningococcal factor H binding protein
CA2792683A1 (en)2010-03-102011-09-15Glaxosmithkline Biologicals S.A.Neisserial fhbp vaccine composition
BR112012022800A2 (pt)*2010-03-112018-05-15Glaxosmithkline Biologicals Sacomposição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica
WO2011161653A1 (en)2010-06-252011-12-29Novartis AgCombinations of meningococcal factor h binding proteins
RU2013108881A (ru)2010-07-302014-09-10Гриффит ЮниверситиРЕКОМБИНАНТНЫЕ ПОРИНОВЫЕ БЕЛКИ Por A Neisseria meningitidis
CN103189071A (zh)2010-08-232013-07-03惠氏有限责任公司脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
GB201014967D0 (en)*2010-09-092010-10-20Univ SouthamptonComposition
MX362802B (es)2010-09-102019-02-13Wyeth Llc StarVariantes no lipidadas de antigenos orf2086 de neisseria meningitidis.
GB201015132D0 (en)*2010-09-102010-10-27Univ BristolVaccine composition
AU2011300418B2 (en)2010-09-102016-05-12Glaxosmithkline Biologicals SaMeningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
EP2635593B1 (en)*2010-11-052016-09-14Institut National de la Sante et de la Recherche Medicale (INSERM)Vaccines for preventing meningococcal infections
GB201102090D0 (en)*2011-02-082011-03-23Univ SheffieldAntigenic polypeptide
GB201120634D0 (en)*2011-11-302012-01-11Univ SheffieldAdjuvant polypeptide
US9657297B2 (en)*2012-02-022017-05-23Glaxosmithkline Biologicals SaPromoters for increased protein expression in meningococcus
JP5925342B2 (ja)2012-03-092016-05-25ファイザー・インク髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法
SA115360586B1 (ar)2012-03-092017-04-12فايزر انكتركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2876138C (en)2012-06-142023-09-19Novartis AgVaccines for serogroup x meningococcus
GB201211154D0 (en)*2012-06-222012-08-08Univ SouthamptonComposition
AU2013295242C1 (en)2012-07-272018-08-09Institut National De La Sante Et De La Recherche MedicaleCD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
EP2964665B1 (en)2013-03-082018-08-01Pfizer IncImmunogenic fusion polypeptides
US9725701B2 (en)2013-03-152017-08-08Iowa Corn Promotion BoardProkarytoic-type isocitrate dehydrogenase and its application for improving nitrogen utilization in transgenic plants
EP4098276A1 (en)2013-09-082022-12-07Pfizer Inc.Neisseria meningitidis compositions and methods thereof
WO2016091902A1 (en)*2014-12-092016-06-16Sanofi PasteurCompositions comprising n. meningitidis proteins
KR20190049940A (ko)2015-02-192019-05-09화이자 인코포레이티드나이세리아 메닌지티디스 조성물 및 그의 방법
EP4309670A3 (en)2016-09-022024-07-17Sanofi Pasteur, Inc.Neisseria meningitidis vaccine
PE20191107A1 (es)2017-01-312019-08-26PfizerComposiciones de neisseria meningitidis y metodos respectivos
WO2020023717A2 (en)*2018-07-252020-01-30The Trustees Of Indiana UniversityDiagnostic assay for a strain of neisseria meningitidis
CA3155669A1 (en)2019-09-272021-04-01Pfizer Inc.Neisseria meningitidis compositions and methods thereof
US11618902B2 (en)*2020-03-302023-04-04Jiangnan UniversityBacillus subtilis for producing N-acetylneuraminic acid and application thereof
CN111394410B (zh)*2020-03-302022-02-01江南大学一种高催化活性神经氨酸合酶及应用
US11579093B2 (en)2020-04-222023-02-14SciLogica Corp.Optical component
US10973908B1 (en)2020-05-142021-04-13David Gordon BermudesExpression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE2848965A1 (de)1978-11-111980-05-22Behringwerke AgVerfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4239749A (en)*1979-09-271980-12-16United States Of AmericaNeisseria gonorrhoeae vaccine
EP0273116A3 (en)1986-10-091990-05-02Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Gonococcal and meningococcal polypeptides, vaccines and diagnostics
RU2023448C1 (ru)1987-07-301994-11-30Сентро Насьональ Де БиопрепарадосСпособ получения вакцины против различных патогенных серотипов менингита нейссера группы в
NL8803111A (nl)*1988-12-191990-07-16Nederlanden StaatMultivalent meningococcen klasse i buitenmembraaneiwit vaccin.
EP0467714A1 (en)1990-07-191992-01-22Merck & Co. Inc.The class II protein of the outer membrane of neisseria meningitidis
DE69227898T2 (de)1991-03-141999-05-12Imclone Systems, Inc., New York, N.Y.Rekombinante hybride porinepitope
FR2692592B1 (fr)1992-06-191995-03-31Pasteur Merieux Serums VaccFragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
ES2145072T3 (es)1993-05-132000-07-01American Cyanamid CoPreparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
US5439808A (en)1993-07-231995-08-08North American Vaccine, Inc.Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
EP0710118B1 (en)1994-04-201998-11-25U.S. Department Of The ArmyVaccine against gram-negative bacterial infections
FR2720408B1 (fr)1994-05-311996-08-14Pasteur Merieux Serums VaccFragments Tbp2 de Neisseria meningitidis.
IL117483A (en)1995-03-172008-03-20Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en)1995-05-182001-01-30University Of MarylandVaccine delivery system
ES2217325T5 (es)*1995-09-182009-04-01United States Army Medical Research Materiel Command (Usamrmc)Metodos mejorados para la produccion de vacunas de subunidades multivalentes de proteosomas acomplejados no covalentemente.
FR2739624B1 (fr)1995-10-101997-12-05Pasteur Merieux Serums VaccNouvelle sous-unite tbp2 de neisseria meningitidis
AU2115897A (en)1996-02-011997-08-22North American Vaccine, Inc.Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines
WO1998017805A2 (en)1996-10-241998-04-30THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, c/o Centers for Disease Control and Prevention, Technology Transfer OfficeInvasion associated genes from neisseria meningitidis serogroup b
PT942983E (pt)1996-10-312007-02-28Human Genome Sciences IncAntigénios e vacinas de streptococcus pneumoniae
AU748973B2 (en)1997-07-172002-06-13Baxter Healthcare SaImmunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide
ES2275314T3 (es)*1997-08-152007-06-01Rijksuniversiteit UtrechtProteina de neisseria de union a lactoferrina.
JP4472866B2 (ja)*1997-11-062010-06-02カイロン ソチエタ ア レスポンサビリタ リミタータナイセリア抗原
US6914131B1 (en)1998-10-092005-07-05Chiron S.R.L.Neisserial antigens
GB9726398D0 (en)1997-12-121998-02-11Isis InnovationPolypeptide and coding sequences
AU1979599A (en)*1998-01-141999-08-02Chiron S.P.A.(neisseria meningitidis) antigens
GB9808866D0 (en)1998-04-241998-06-24Smithkline Beecham BiologNovel compounds
US20070026021A1 (en)1998-05-012007-02-01Chiron S.R.I.Neisseria meningitidis antigens and compositions
BR9910089A (pt)*1998-05-012004-06-08Chiron CorpComposições e antìgenos de neisseria meningitidis
AT2941U1 (de)1998-05-061999-07-26Fleischhacker GerhardFlexible flüssigkeitssperre
DE69934225T2 (de)1998-05-292007-09-27Novartis Vaccines and Diagnostics, Inc., EmeryvilleKombinierte meningitis b/c impfstoffe
EP1741443B1 (en)1998-05-292014-05-21Novartis Vaccines and Diagnostics, Inc.Combination meningitidis B/C vaccines
US6248329B1 (en)1998-06-012001-06-19Ramaswamy ChandrashekarParasitic helminth cuticlin nucleic acid molecules and uses thereof
BR9914374A (pt)*1998-10-092002-09-17Chiron CorpSequências genÈmicas de neisseria e métodos para seu uso
US20030215469A1 (en)1998-11-022003-11-20Microbiological Research AuthorityMulticomponent meningococcal vaccine
GB9823978D0 (en)*1998-11-021998-12-30Microbiological Res AuthorityMulticomponent meningococcal vaccine
ATE279943T1 (de)*1999-02-262004-11-15Chiron SrlVerbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
DK1185691T3 (da)1999-04-302009-06-22Novartis Vaccines & DiagnosticGenomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
ES2397918T3 (es)*1999-04-302013-03-12Novartis Vaccines And Diagnostics S.R.L.Antígenos Neisseriales conservados
DK2270173T3 (en)1999-05-192016-03-07Glaxosmithkline Biolog SaNeisserial combination compositions
GB9911683D0 (en)1999-05-191999-07-21Chiron SpaAntigenic peptides
CN1796404A (zh)1999-10-292006-07-05启龙有限公司奈瑟球菌的抗原性肽
WO2001034642A2 (en)1999-11-122001-05-17University Of Iowa Research FoundationControl of neisserial membrane synthesis
JP2003520248A (ja)2000-01-172003-07-02カイロン エセ．ピー．アー．Ｎ．ｍｅｎｉｎｇｉｔｉｄｉｓ血清型ｂ外膜タンパク質を含む外膜小胞（ｏｍｖ）ワクチン
JP2003523208A (ja)2000-01-252003-08-05ザ ユニバーシティ オブ クイーンズランド髄膜炎菌表面抗原ＮｈｈＡの保存領域を含むタンパク質
CN1201011C (zh)2000-02-282005-05-11启龙股份公司奈瑟球菌蛋白质的异源表达
NO20002828D0 (no)2000-06-022000-06-02Statens Inst For FolkehelseProteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
AU2001280883A1 (en)2000-07-272002-02-13The Children's Hospital & Research Center At OaklandVaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103171D0 (en)2001-02-082001-03-28Smithkline Beecham BiologVaccine composition
GB0103424D0 (en)*2001-02-122001-03-28Chiron SpaGonococcus proteins
JP2004529643A (ja)2001-04-172004-09-30カイロン コーポレイション機能活性抗体を誘発する髄膜炎菌性ｂエピトープの分子模倣物
GB0118249D0 (en)*2001-07-262001-09-19Chiron SpaHistidine vaccines
RU2323002C2 (ru)2001-07-262008-04-27Чирон Срл.Вакцины, содержащие алюминиевые адъюванты и гистидин
GB0121591D0 (en)2001-09-062001-10-24Chiron SpaHybrid and tandem expression of neisserial proteins
US20050232936A1 (en)*2001-07-272005-10-20Chiron CorporationMeningococcus adhesins nada, app and orf 40
AR045702A1 (es)2001-10-032005-11-09Chiron CorpComposiciones de adyuvantes.
MX339524B (es)2001-10-112016-05-30Wyeth CorpComposiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0130123D0 (en)2001-12-172002-02-06Microbiological Res AgencyOuter membrane vesicle vaccine and its preparation
SI1524993T1 (sl)*2002-08-022013-07-31Glaxosmithkline Biologicals S.A.Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
GB0220194D0 (en)2002-08-302002-10-09Chiron SpaImproved vesicles
US7785608B2 (en)2002-08-302010-08-31Wyeth Holdings CorporationImmunogenic compositions for the prevention and treatment of meningococcal disease
CN1809380B (zh)2002-10-112010-05-12启龙有限公司广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
US20070059329A1 (en)2002-11-152007-03-15Nathalie NoraisUnexpected surface proteins in meningococcus
GB0227346D0 (en)2002-11-222002-12-31Chiron Spa741
WO2004054611A1 (en)2002-12-162004-07-01Nasjonalt FolkehelseinstituttMeningococcal vaccine based on outer membrane proteins porb2 and pora
US20070148729A1 (en)2003-01-152007-06-28Farley John EMethods for increasing neisseria protein expression and compositions thereof
PT1587537E (pt)2003-01-302012-05-30Novartis AgVacinas injetáveis contra múltiplos serogrupos meningocócicos
KR20060019515A (ko)2003-04-162006-03-03와이어쓰 홀딩스 코포레이션수막구균 질환의 예방 및 치료용 신규 면역원성 조성물
GB0315021D0 (en)2003-06-262003-07-30Chiron SrlImmunogenic gonococcal compositions
GB0316560D0 (en)2003-07-152003-08-20Chiron SrlVesicle filtration
GB0323103D0 (en)2003-10-022003-11-05Chiron SrlDe-acetylated saccharides
NZ546430A (en)2003-10-022009-04-30Novartis Vaccines & DiagnosticLiquid vaccines for multiple meningococcal serogroups
CA2550927A1 (en)2003-12-232005-07-14Glaxosmithkline Biologicals S.A.A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection
GB0408977D0 (en)2004-04-222004-05-26Chiron SrlImmunising against meningococcal serogroup Y using proteins
GB0409748D0 (en)2004-04-302004-06-09Chiron SrlLactoferrin cleavage
GB0419408D0 (en)2004-09-012004-10-06Chiron Srl741 chimeric polypeptides
GB0419627D0 (en)2004-09-032004-10-06Chiron SrlImmunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en)2004-10-292004-12-01Chiron SrlImmunogenic bacterial vesicles with outer membrane proteins
DK2682126T3 (en)2005-01-272017-02-27Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis
GB0524066D0 (en)2005-11-252006-01-04Chiron Srl741 ii
TW200806315A (en)2006-04-262008-02-01Wyeth CorpNovel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2008001244A2 (en)2006-06-232008-01-03Harun AksoyA stone
AR064642A1 (es)2006-12-222009-04-15Wyeth CorpPolinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20100150912A1 (en)2007-04-112010-06-17Novartis AgBlocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
RU2009149359A (ru)2007-06-042011-07-20Новартис АГ (CH)Состав вакцин против менингита
WO2009038889A1 (en)2007-08-022009-03-26Children's Hospital And Research Center At OaklandFhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
ES2532946T3 (es)2008-02-212015-04-06Novartis AgPolipéptidos PUfH meningocócicos
WO2009114485A2 (en)2008-03-102009-09-17Children's Hospital & Research Center At OaklandChimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
RU2477145C2 (ru)2008-05-302013-03-10ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИМультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения
WO2010028096A2 (en)2008-09-032010-03-11Children's Hospital & Research Center At OaklandPeptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0816284D0 (en)2008-09-052008-10-15Nat Biolog Standards BoardVaccine
IT1394288B1 (it)2008-09-122012-06-06Novartis Vaccines & DiagnosticImmunogeni di proteine che legano il fattore h.
GB0819633D0 (en)2008-10-252008-12-03Isis InnovationComposition
AU2010227219B2 (en)2009-03-242014-02-27Glaxosmithkline Biologicals S.A.Adjuvanting meningococcal factor H binding protein
AU2010227221B2 (en)2009-03-242015-01-22Novartis AgCombinations including pneumococcal serotype 14 saccharide
CA2792683A1 (en)2010-03-102011-09-15Glaxosmithkline Biologicals S.A.Neisserial fhbp vaccine composition
TR201802933T4 (tr)2010-03-302018-03-21Childrens Hospital & Res Center At OaklandÖzellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
US9427476B2 (en)2012-05-242016-08-30The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesMultivalent meningococcal conjugates and methods for preparing conjugates

Also Published As

Publication numberPublication date
CA2838395C (en)2016-07-19
EP1860191A3 (en)2008-02-13
JP5622344B2 (ja)2014-11-12
AU2006201153B2 (en)2008-12-11
US20050244436A1 (en)2005-11-03
AU5097700A (en)2000-12-12
EP2270174A1 (en)2011-01-05
MXPA01011867A (es)2002-05-06
US20070231342A1 (en)2007-10-04
US20150174231A1 (en)2015-06-25
NZ536676A (en)2006-11-30
US9364528B1 (en)2016-06-14
ES2563650T3 (es)2016-03-15
PT2270173E (pt)2016-03-28
AU2009200865B2 (en)2012-11-08
EP2270173A1 (en)2011-01-05
CN102580072A (zh)2012-07-18
JP2003500420A (ja)2003-01-07
DK2270172T3 (en)2016-02-29
NZ545647A (en)2008-02-29
US20120135026A1 (en)2012-05-31
EP2270172B1 (en)2016-01-13
AU2006201153A1 (en)2006-04-13
BR0010721A (pt)2002-06-11
CA2373236A1 (en)2000-11-30
CN1362992A (zh)2002-08-07
JP2013047274A (ja)2013-03-07
US20110104193A1 (en)2011-05-05
EP1179072A2 (en)2002-02-13
AU2009200865A1 (en)2009-03-26
CY1117235T1 (el)2017-04-05
CN100338218C (zh)2007-09-19
US20160151476A1 (en)2016-06-02
EP2258851A1 (en)2010-12-08
EP2270172A1 (en)2011-01-05
US7862827B2 (en)2011-01-04
EP2270173B1 (en)2016-01-06
US20140037668A1 (en)2014-02-06
NZ528254A (en)2005-07-29
DK2270173T3 (en)2016-03-07
US9610342B2 (en)2017-04-04
CA2838395A1 (en)2000-11-30
CA2373236C (en)2014-08-26
CA2929348A1 (en)2000-11-30
AU783894B2 (en)2005-12-22
US20170165346A1 (en)2017-06-15
NZ515935A (en)2004-01-30
WO2000071725A3 (en)2001-06-28
PT2270172E (pt)2016-03-31
US20160175422A1 (en)2016-06-23
CY1117239T1 (el)2017-04-05
JP2007224047A (ja)2007-09-06
WO2000071725A2 (en)2000-11-30
EP1860191A2 (en)2007-11-28

Similar Documents

PublicationPublication DateTitle
ES2563677T3 (es)Composiciones de combinaciones de Neisseria
ES2505695T3 (es)Composiciones inmunógenas para Streptococcus pyogenes
ES2596880T3 (es)Composición para el análisis de glicoproteínas
ATE218579T1 (de)Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen
ATE333464T1 (de)Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
ATE174905T1 (de)Wasserlösliche organische salze von kreatin
DE69532760D1 (de)Mittel zur verabreichung von antigenen
DE60233532D1 (de)An proteinphosphatase 2a bindende synthetische ode anwendungen
DK0690872T3 (da)Biologisk aktive peptider fra funktionelle domæner af baktericidt/permeabilitetsforøgende protein og anvendelser deraf
DE50112802D1 (de)Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE59410380D1 (de)Endosomolytisch wirksame partikel
EP0585257A4 (en) DNA AND AMINO ACID SEQUENCE SPECIFIC TO NATURAL K KILLER CELLS.
ATE223728T1 (de)Stabilisierte pharmazeutische zusammensetzung von bdnf
EP1548107A4 (en) CHROMOPROTEIN AND FLUORO PROTEINS
ATE193022T1 (de)Heparin-und sulfatid-bindende peptide vom typ 1 der wiederkehrenden sequenzen vom menschlichen thrombospondin
ATE439441T1 (de)Veränderte, fluoreszierende proteine
CO5570658A2 (es)Composicion y metodo para el tratamiento de la diabetes
ES2507094T3 (es)Proteína específica del timo
PT1276763E (pt)Proteinas anti-congelantes sua producao e utilizacao
ATE323763T1 (de)Dna & protein bindende miniatur proteine
PT1131408E (pt)Acidos oligossacarido-aldonicos e sua utilizacao topica
DE50108409D1 (de)Behandlung von oberflächen zur temporären verbesserung des schmutzablöseverhaltens
BR9809103A (pt)Forma farmacêutica estável de administração para peptìdeos, proteìnas e ácidos nucléicos
DK1219301T3 (da)Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
ATE474589T1 (de)Angiogene peptide und ihre verwendungen
[8]ページ先頭
©2009-2025 Movatter.jp